Company profile
MEDICINOVA INC
NASDAQ:MNOVBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IBUDILAST | phase2_3 | — | 8 | active |
| BEDORADRINE SULFATE | phase2 | — | 4 | no active trials |
| TIPELUKAST | phase2 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02714036 | phase1_2 | completed | 2016-05-06 | 2019-12-31 | MediciNova | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) |
| NCT04429555 | phase2 | completed | 2021-01-11 | 2022-06-30 | MediciNova | Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS |
| NCT01013142 | phase1 | completed | 2009-11-01 | 2010-03-01 | MediciNova | Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) |
| NCT04057898 | phase2_3 | active_not_recruiting | 2020-05-28 | 2027-04-01 | MediciNova | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS |
| NCT02238626 | phase2 | completed | 2014-09-01 | 2017-08-01 | MediciNova | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
FDA applications (0)
No records yet.